Characterizing the impact of teriflunomide on adaptive immune cell subsets, repertoire and function in patients with relapsing-remitting MS: TERI-DYNAMIC

Wiendl H, Gross CC, Lindner M, Eschborn M, Weisser L, Posevitz-Fejfar A, Schulte-Mecklenbeck A, Van Wijmeersch B, Hupperts R, Lunven C, Brette S, Turner TJ, Klotz L (2015)

In: ECTRIMS, Barcelona, Spanien.

Abstract in Online-Sammlung (Konferenz)

Comparison and Correlation of Two Proposed PML Risk Stratification Biomarkers for Long-term Natalizumab Treatment, Anti-JCV Antibody Index and L-selection (CD62L): A Retrospective Study

Schwab N, Schneider-Hohendorf T, Breuer J, Posevitz-Fejfar A, Wiendl H, Posevitz-Fejfar A (2014)

In: Neurology, 83(2).

Forschungsartikel (Zeitschrift)

The bile acid receptor FXR controls CNS autoimmunity in an IL-10-dependent fashion

Hucke S, Herold M, Liebmann M, Posevitz-Fejfar A, Kuhlmann T, Wiendl H, Klotz L (2014)

In: Journal of Neuroimmunology, 275(1-2, SI).

Forschungsartikel (Zeitschrift)

Fingolimod treatment promotes regulatory B-cell phenotype and function in multiple sclerosis

Gruetzke B, Hucke S, Wildemann B, Dehmel T, Kieseier B, Posevitz-feijfar A, Wiendl H, Klotz L (2014)

In: Journal of Neuroimmunology, 275(1-2, SI).

Forschungsartikel (Zeitschrift)

L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H (2013)

In: Neurology, 2013.

Forschungsartikel (Zeitschrift)

Publikationen

Kontakt

Top-Links

Impaired DNAM-1/CD155 interaction in MS disrupts NK-mediated immune regulation of T-cell activity and is reconstituted by therapeutic modulation of the IL-2 receptor Gross CC, Schulte-Mecklenbeck A, Ruenzi A, Kuhlmann T, Posevitz-Fejfar A, Schwab N, Schneider-Hohendorf T, Held K, Konjevic M, Dornmair K, Hohlfeld R, Elkins J, Ziemssen T, Meuth SG, Wiendl H (2015) In: ECTRIMS, Barcelona, Spanien. Abstract in Online-Sammlung (Konferenz)
Characterizing the impact of teriflunomide on adaptive immune cell subsets, repertoire and function in patients with relapsing-remitting MS: TERI-DYNAMIC Wiendl H, Gross CC, Lindner M, Eschborn M, Weisser L, Posevitz-Fejfar A, Schulte-Mecklenbeck A, Van Wijmeersch B, Hupperts R, Lunven C, Brette S, Turner TJ, Klotz L (2015) In: ECTRIMS, Barcelona, Spanien. Abstract in Online-Sammlung (Konferenz)
The Neuroinflammation Biobank in the Department of Neurology, University Hospital Muenster, Germany Posevitz-Fejfar A, Wiendl H (2014) In: Biopreservation and Biobanking, 12(1). Forschungsartikel (Zeitschrift)
Comparison and Correlation of Two Proposed PML Risk Stratification Biomarkers for Long-term Natalizumab Treatment, Anti-JCV Antibody Index and L-selection (CD62L): A Retrospective Study Schwab N, Schneider-Hohendorf T, Breuer J, Posevitz-Fejfar A, Wiendl H, Posevitz-Fejfar A (2014) In: Neurology, 83(2). Forschungsartikel (Zeitschrift)
JCV index and L-selectin for natalizumab-associated PML risk stratification Schwab N, Schneider-Hohendorf T, Breuer J, Posevitz-Fejfar A, Wiendl H (2014) In: Multiple Sclerosis, 20(1). Forschungsartikel (Zeitschrift)
The bile acid receptor FXR controls CNS autoimmunity in an IL-10-dependent fashion Hucke S, Herold M, Liebmann M, Posevitz-Fejfar A, Kuhlmann T, Wiendl H, Klotz L (2014) In: Journal of Neuroimmunology, 275(1-2, SI). Forschungsartikel (Zeitschrift)
The pathophysiological role of cytotoxic CD8 T cells in Susac syndrome Bhatia U, Schneider-Hohendorf T, Posevitz-Fejfar A, Schwab N, Meuth SG, Wiendl H, Kleffner I, Gross CC (2014) In: 12th International Congress of Neuroimmunology (ISNI), Mainz, Deutschland. Abstract in Online-Sammlung (Konferenz)
Fingolimod treatment promotes regulatory B-cell phenotype and function in multiple sclerosis Gruetzke B, Hucke S, Wildemann B, Dehmel T, Kieseier B, Posevitz-feijfar A, Wiendl H, Klotz L (2014) In: Journal of Neuroimmunology, 275(1-2, SI). Forschungsartikel (Zeitschrift)
JCV index and L-selectin for natalizumab-associated PML risk stratification Schwab N, Schneider-Hohendorf T, Breuer J, Posevitz-Fejfar A, Wiendl H (2014) In: Journal of Neuroimmunology, 275(1-2, SI). Forschungsartikel (Zeitschrift)
L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H (2013) In: Neurology, 2013. Forschungsartikel (Zeitschrift)